Stefan Pflanz
Director Boehringer-Ingelheim Venture Fund USA at Boehringer Ingelheim
United States
Overview
Work Experience
Executive Director Boehringer-Ingelheim Venture Fund USA
2020 - Current
BoD roles: Actym; https://www.actymthera.com/; 2020 - present Bodyport; https://www.bodyport.com/; 2021 - present Oncomyx; https://www.oncomyx.com/; 2020 - 2023 TigaTx; https://www.tigatx.com; 2021 -present
Director Cancer Immunology and Immune Modulation
2016 - 2020
Senior Research Scientist
2011 - 2016
Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases.
Raised $4,413,500,000.00 from Abingworth.
Visiting Scientist in Department of Dermatology
2010 - 2011
Performed experiments interrogating neuro-immune networks involved in regulation of inflammatory skin diseases.
Head of Cytokine Biology
2006 - 2010
Led target identification and validation research with a focus on biologics for therapeutic modulation of immune-related cytokine pathways. Managed a research lab with four direct reports and eight project-related reports in support labs. Reported to Site Head.
Schering-Plough Corporation is a major U.S.-based manufacturer of pharmaceuticals.
Head of Target Research
2004 - 2006
Supervised target identification research and target validation efforts around molecules suitable for therapeutic intervention with antibodies or antibody fragments in the areas of inflammation and oncology. Bore responsibility for optimization of lead candidate antibody molecules according to desired specifications. Managed Target Research Team with five direct reports. Reported to CSO.
Group Leader SCA Therapeutics
2003 - 2004
Oversaw identification and characterization of therapeutic single chain antibodies (SCAs) for treatment of inflammatory disorders. Managed three direct reports. Reported to SCA Unit Head.
Postdoctoral Fellow
2000 - 2002
Discovered and first characterized novel cytokine Interleukin-27.
PhD student
1996 - 1999
Education
PhD
1996 - 1999